Myriad Genetics: In the Eye of a Policy Storm

59 Pages Posted: 12 Sep 2008

See all articles by E. Richard Gold

E. Richard Gold

McGill University - Faculty of Law

Julia Carbone

affiliation not provided to SSRN

Date Written: September 9, 2008


From the late 1980s, a storm surrounding the wisdom, ethics and economics of human gene patents has been brewing. The various winds of concern in this storm touched on the impact of gene patents on basic and clinical research, on health care delivery, and on the ability of public health care systems to provide equal access when faced with costly patented genetic diagnostic tests. Myriad Genetics, Inc. along with its subsidiary, Myriad Genetic Laboratories, Inc., a small Utah-based biotechnology company, found itself unwittingly in the eye of this storm after a series of decisions it made regarding the commercialization of a hereditary breast cancer diagnostic test. This case study examine the background to Myriad's decisions, the context in which these decisions were made and the policy, research and business response to them.

Keywords: Myriad Genetics, genes, patents, ethics, business models, public health care, clinicial genetics, Europe, Canada, Australia, Japan

Suggested Citation

Gold, E. Richard and Carbone, Julia, Myriad Genetics: In the Eye of a Policy Storm (September 9, 2008). Available at SSRN: or

E. Richard Gold (Contact Author)

McGill University - Faculty of Law ( email )

3644 Peel Street
Montreal H3A 1W9, Quebec

Julia Carbone

affiliation not provided to SSRN

Do you have a job opening that you would like to promote on SSRN?

Paper statistics

Abstract Views
PlumX Metrics